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Abstract: Background and Objective: Radium-223 dichloride (Xofigo®) is a calcium mimetic agent
approved for the treatment of castration-resistant prostate cancer patients with symptomatic bone
metastases and no known visceral metastatic disease. This targeted, α-particle-emitting therapy has
demonstrated significant survival benefit accompanied by a favorable safety profile. Nevertheless,
recent evidence suggests that its combined use with abiraterone and prednisone/prednisolone may be
associated with increased risk of death and fractures. While the precise pathophysiologic mechanisms
of these events are not yet clear, collecting evidence from more clinical trials and translational studies
is necessary. The aim of our present study is to assess whether accessible sources of patient outcome
data can help gain additional clinical insights to radium-223 dichloride’s safety profile. Materials
and Methods: We performed a retrospective analysis of cases extracted from the FDA Adverse Event
Reporting System and characterized side effect occurrence by using reporting ratios. Results: A
total of ~1500 prostate cancer patients treated with radium-223 dichloride was identified, and side
effects reported with the use of radium-223 dichloride alone or in combination with other therapeutic
agents were extracted. Our analysis demonstrates that radium-223 dichloride may often come with
hematological-related reactions, and that, when administered together with other drugs, its safety
profile may differ. Conclusions: While more prospective studies are needed to fully characterize
the toxicological profile of radium-223 dichloride, the present work constitutes perhaps the first
effort to examine its safety when administered alone and in combination with other agents based on
computational evidence from public real-world post marketing data.
Keywords: prostate cancer; bone metastases; radium-223 dichloride (Xofigo®); side effects; real
world data; data mining; pharmacoepidemiology; proportional reporting ratio
1. Introduction
Development of bone metastases represents a pivotal incident in the clinical course of prostate
cancer (PC), associated with the appearance of skeletal-related events, a decrease in quality of life and
an increase in mortality [1,2]. The skeleton is the major metastatic site in PC with more than 90% of
patients dying from PC having bone metastases [3]. Several classes of bone-targeting therapies have
been developed and introduced in clinical practice for the treatment of PC-related bone metastases,
some of which have a proven capacity to improve survival, and others with rather supportive or
palliative role.
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Historically, radionuclide therapy has been applied for decades in the treatment of bone metastases
with bone-modifying, β-particle-emitting agents (like strontium-89 and samarium-153), but their use
has been mainly palliative and without clear survival benefit when applied as monotherapy [2]. Unlike
previous radiopharmaceuticals, radium-223 dichloride (Xofigo®) [4,5] has been the first targeted,
α-particle-emitting agent to show a survival benefit in castration-resistant PC (CRPC) patients with
bone metastases, as demonstrated in the landmark ALSYMPCA trial [6]. This study demonstrated an
improvement of overall survival as well as delaying of time to first symptomatic skeletal event with
the use of radium-223 dichloride, and led to its Food and Drug Administration (FDA) approval in
2013 for the treatment of CRPC patients with symptomatic bone metastases and no known visceral
metastatic disease.
Besides its efficacy in controlling metastatic bone disease, the ALSYMPCA trial highlighted another
significant feature of radium-223 dichloride, namely its favorable safety profile; ALSYMPCA’s final
long-term safety analysis confirmed low myelosuppression incidence and further showed that treatment
remained well tolerated, with no new safety concerns [6–8]. These results suggested the suitability of
the agent for combined use with other medications. Initial results regarding concurrent administration
of radium-223 dichloride with docetaxel or anti-androgen therapies seemed promising regarding
tolerance and safety of the concomitant therapies [9–11]. Nevertheless, recent preliminary data of an
ongoing, double-blind, placebo-controlled phase III trial in metastatic CRPC comparing radium-223
dichloride with placebo, both given in combination with abiraterone and prednisone/prednisolone,
have indicated that combined use of these medications may be associated with increased risk of
death and fractures [12–14]. Based on these results, the European Medicines Agency (EMA) has
recommended that the use of the combination therapy radium-223 dichloride with abiraterone and
prednisone/prednisolone should be restricted [12–14]. Safety-related warning and precautionary
information was also accordingly updated in radium-223 dichloride’s FDA label [15].
Inspired by these developments and the importance of radium-223 dichloride in the treatment of
PC patients, we searched for sources of accessible real-world data and attempted to characterize its
safety profile. Specifically, we analyzed adverse events (AEs) from the FDA’s Adverse Event Reporting
System (FAERS) and extracted side effects reported in PC patients treated with radium-223 dichloride
alone or in combination with other therapeutic agents. Last, we share our findings with the community
to support the current efforts to characterize evidence regarding radium-223 dichloride’s safety.
2. Materials and Methods
For the side effect profiling of radium-223 dichloride we relied on the analysis of 7.9 million AEs
extracted from the public FAERS dataset (incl. 2017Q2).
2.1. Data Integration
The dataset held information regarding patients’ treatments (medications) and indications (disease
or condition), as well as the reported reactions and outcomes (e.g., “death” or “hospitalization”)
observed in AEs. To compensate for ambiguities introduced by the non-standardized use of drug
names [16], medications reported via free text in FAERS were consolidated and via a stepwise process
matched to standardized dictionaries [17]. This drug-centric integration process allowed drugs to be
further categorized according to the Anatomical Therapeutic Chemical (ATC) classification system.
Indications and reactions, coded by FAERS in terms from the Medical Dictionary for Regulatory
Activities (MedDRA), were further contextualized by using its full hierarchical structure.
2.2. Statistical analysis
Using this dataset, we could then define two AE cohorts:
• Cohort A: 1021 patients treated with radium-223 dichloride alone.
• Cohort B: 542 patients treated not only with radium-223 dichloride, but also with other drugs.
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For the statistical characterization of the two cohorts, we employed the proportional reporting
ratio (PRR) metric, using the approach described by van Puijenbroek et al. [18]. PRR is an established
measure of disproportionality in pharmacovigilance and a valuable statistical aid to the evaluation of
signals generated from spontaneous reporting data [19]. Each cohort was characterized with respect to
the occurrence of drugs, serious outcomes, and indications and reactions. We also considered relevant
statistical significance be reflected by Fisher’s exact test p-values (two-tailed).
Results for each cohort A and B are summarized in the corresponding Supplementary files A and
B, respectively. The supplementary files also contain drug descriptions in terms from the different levels
of the ATC categorization, and indications and reactions are accordingly described in terms from the
different levels of the MedDRA hierarchy. Results per cohort list the observed case counts (i.e., number
of AEs a certain occurrence was observed in), percentage of cohort cases, the PRR disproportionality
score, and Fisher’s test p-values. The Supplementary files contain for consideration by the community
all observations irrespective of their PRR or Fisher’s exact test signals. For this study, we considered a
p-value of 5% or lower to indicate statistical significance (i.e., when p-value < 0.05).
3. Results
In total, 1563 AEs involving radium-223 dichloride therapy were identified: 1021 cases reported
treatment with radium-223 dichloride only (Cohort A), whereas in the remaining 542 cases patients
were treated with other drugs as well (Cohort B). Of the total radium-223 dichloride set of AEs, 1121
cases explicitly linked to an indication, 1027 of which (91.6%) confirmed use in PC patients. We
manually examined the comorbidities mentioned in the set and found that they included primarily
metastatic (bone) disease. Considering that radium-223 dichloride is specifically approved for the
treatment of CRPC patients, it was concluded that the identified AE cases adequately reflect its use in
clinical practice. We therefore decided to investigate the whole set of 1563 AEs and keep the pool of
side effect observations as broad as possible.
Moreover, we examined and confirmed that drugs co-medicated with radium-223 dichloride
in Cohort B (apart from Xofigo®, another 444 drug records matched in this AE set) properly reflect
the oncological clinical practice in CRPC with osseous metastases. Specifically, the most frequently
co-medicated category was anti-androgens, reported in 197 AEs of this set (i.e., 36.35% of those cases,
and with the highest PRR signal 94.84), while other frequently co-administered treatment categories
included glucocorticoids, opioids and other analgesics, as well as bisphosphonates.
3.1. Outcome Analysis
We examined serious outcomes reported in radium-223 dichloride’s AEs—Table 1 lists percentage
(%) of cases per cohort that have the respective outcome reported. Overall, patients treated with
radium-223 dichloride (cohort noted as ‘A ∪ B’ in Table 1) had somewhat less occurrence of Death, Life
threatening and Hospitalization cases than reported for the average PC or cancer patient in FAERS.
In addition, we noticed that cohort B patients tend to suffer worse outcomes than in cohort A. This
likely reflects a situation in which cohort B patients—treated with multiple drugs, rather than with
radium-223 dichloride alone—may have experienced more complicated disease conditions (e.g., larger
tumor burden or multiple comorbidities). Nonetheless, no definitive conclusions can be drawn directly
from the present dataset alone.
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Table 1. Selected serious outcomes reported in AEs.
Outcome
Cohort (%)
A B A ∪ B 1 PC 2 Cancer 3 FAERS
Death 18.81 23.43 20.41 26.35 24.71 10.11
Life
threatening 1.76 5.17 2.94 3.22 5.02 3.03
Hospitalization 23.99 48.71 32.57 30.15 35.37 1 24.36
1 This cohort refers to the union of the patients included in sets A and B, namely all 1563 patients treated with
radium-223 dichloride. 2 Prostate cancer (PC) cases were defined as those AEs that have indications linked to the
High Level Term (HLT) of MedDRA (3rd level category) named Prostatic neoplasms malignant. 3 Cancer AEs were
defined as cases with indications linked to the System Organ Class (SOC) of MedDRA (level 1 category) called
Neoplasms benign, malignant and unspecified (incl. cysts and polyps).
3.2. Side Effect Profiling
Next, we compared the occurrence of reactions mentioned in each cohort A and B. We examined
reactions at the Preferred Term (PT) level of MedDRA (level 4 categories), and excluded from the
analysis terms that reflected tumor/staging status (e.g., PC, disease progression, metastasis to bone),
that were unspecific (e.g., laboratory test abnormal, pain) or that did not represent drug-induced effects
(e.g., underdose, drug ineffective). Table 2 summarizes the twenty such most frequently reported
reactions in each cohort (see also Supplementary files A and B). The table juxtaposes the relative order
(#Rank) of each reaction per cohort based on its frequency in that set, the number of cases (AEs) and
percentage of that cohort’s AEs (%Set) that had the respective reaction reported, and the corresponding
PRR score per cohort. Our FAERS analysis could recapitulate several known side effects listed in
radium-223 dichloride’s label. Overall, cohort A had fewer side effects reported than cohort B, despite
its larger patient population. In specific, a total of 598 MedDRA PTs (level 4 terms) were linked to
cohort B whereas, in comparison, 499 were described in cohort A.
Table 2. Most frequently reported side effects per cohort.
Side Effect (Reaction) Cohort A: Only Xofigo Cohort B: Xofigo and Other Drugs
Name #Rank AEs %Set PRR #Rank AEs %Set PRR
Haemoglobin decreased 1 1 73 7.14985 11.07178 16 20 3.69004 5.7086
Nausea 2 + 51 4.9951 1.16074 3 64 11.80812 2.74418
Platelet count decreased 2 3 43 4.21156 7.52259 14 26 4.79705 8.56563
Malaise 4 39 3.81978 1.56369 15 21 3.87454 1.58605
Diarrhoea 5 + 38 3.72184 1.25585 4 50 9.22509 3.11315
Anaemia 1 6 35 3.42801 2.98228 2 65 11.99262 10.43733
Bone pain 7 35 3.42801 10.41557 7 32 5.90406 17.93774
Vomiting 8 + 34 3.33007 1.27435 8 30 5.53506 2.11824
Blood count abnormal 3 9 33 3.23213 43.82126 >20 6 1.10701 14.94108
Fatigue 10 + 31 3.03624 0.83291 1 90 16.60517 4.5564
Thrombocytopenia 2 11 29 2.84035 4.80398 9 30 5.53506 9.36238
Asthenia 12 + 25 2.44858 1.17253 6 41 7.56458 3.62295
Pneumonia 13 + 21 2.05681 1.27006 >20 17 3.13653 1.93684
Pancytopenia 14 20 1.95886 5.98948 11 27 4.98155 15.23674
White blood cell count
decreased 15 19 1.86092 3.48364 >20 10 1.84502 3.45335
Bone marrow failure 3 16 18 1.76298 12.42202 >20 + 5 0.92251 6.49296
Decreased appetite 17 + 17 1.66503 1.31554 5 45 8.30258 6.56207
Back pain 18 + 15 1.46915 1.13896 10 28 5.16605 4.00575
Weight decreased 19 + 14 1.3712 0.949 12 27 4.98155 3.44827
Neutrophil count
decreased 20 12 1.17532 6.49458 >20
+ 3 0.55351 3.05684
Pyrexia >20 + 13 1.27326 0.65169 19 18 3.32103 1.69995
Dyspnoea >20 + 9 0.88149 0.28814 13 26 4.79705 1.56826
Osteonecrosis >20 + 9 0.88149 2.34167 17 19 3.50554 9.31611
Arthralgia >20 + 8 0.78355 0.40463 18 19 3.50554 1.81054
Headache >20 + 5 0.48972 0.14564 20 18 3.32103 0.98778
1 The ‘Haemoglobin decreased’ and ‘Anaemia’ terms refer to the same condition. 2 The terms ‘Platelet count
decreased’ and ‘Thrombocytopenia’ refer to the same condition. 3 ‘Blood count abnormal’ and ‘Bone marrow failure’
refer to the same condition. + Reactions occurring in less than 1% of the respective cohort’s cases, that were found to
not be statistically significant (p-value > = 0.05), or both.
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Furthermore, hematological side effects had strong signals for both cohorts (examples mentioned
next refer all to statistically significant observations per set, with p-value <0.05):
• General hematotoxicity reactions include examples such as the PT Blood count abnormal with
strong signal for both cohorts A (3.23%, PRR = 43.82) and B (1.11%, PRR = 14.94), as well as the
term Bone marrow failure (1.76%, PRR = 12.42) for Set A.
• Red blood cell reactions include examples such as Haemoglobin decreased (Set A: 7.15%, PRR =
11.07; Set B: 3.69%, PRR = 5.71) or Anaemia (Set A: 3.43%, PRR = 2.98; Set B: 11.99%, PRR = 10.44).
• White blood cell reactions include terms like White blood cell count decreased (Set A: 1.86%, PRR =
3.48; Set B: 1.85%, PRR = 3.45) or Leukopenia (Set B: 2.21%, PRR = 8.39).
• Thrombocytopenia (Set A: 2.84%, PRR=4.8; Set B: 5.54%, PRR = 9.36) or Platelet count decreased
(Set A: 4.21%, PRR = 7.52; Set B: 4.8%, PRR = 8.57).
• Neutropenia (Set B: 1.29%, PRR = 2.36), Febrile neutropenia (Set B: 1.29%, PRR = 4.24), or Neutrophil
count decreased (Set A: 1.18%, PRR = 6.5).
• Pancytopenia (Set A: 1.96%, PRR = 5.99; Set B: 4.98%, PRR = 15.24)
In line with the known toxicological profile of the agent [4,5], we found that gastrointestinal
effects (such as nausea, diarrhea and vomiting) were frequently reported. The list of the top most
reported reactions (Table 2) also included effects reflecting a general health deterioration status (such
as malaise, fatigue and asthenia) as well as reactions that referred to nutrition (e.g., decreased appetite
and weight), bone and back pain events. Regarding other known side effects of radium-223 dichloride,
we found that it was not easy to clearly determine their extent. For example, while the signal for some
types of injection site reactions could be captured at the level of more general MedDRA categories (e.g.,
MedDRA HLT ‘Oedema NEC’ linked to 1.86% and 3.14% of cohorts A and B, respectively), others could
not be further summarized because they had either too few occurrences or could only be expressed at
more detailed MedDRA levels (e.g., erythema). The full characterization of Cohorts A and B can be
found in Supplementary files A and B, respectively.
4. Discussion
In an attempt to investigate the side effects of radium-223 dichloride, applied alone or in
combination with other therapeutic agents, we examined respective reaction occurrence in AEs
extracted from public FAERS data. FAERS contains valuable AE information for a large number of
patients (7.9 million cases) coming directly from healthcare professionals, consumers, and manufacturers.
Our results are thus based on real world events and aim to provide additional insight to previous and
current radium-223 dichloride safety profiling efforts.
Overall, we found that the larger cohort A (in which patients were treated only with radium-223
dichloride) had fewer side effects reported than the smaller Cohort B (in which patient therapy included
additional treatments). While this may be somewhat expected due to the effects that the other drugs
may introduce, looking at the data alone cannot provide a causative explanation. In addition, the
variability between the two cohorts’ profiles may be attributable to their relative size difference, to
the co-medications’ own side effects, and also to potential combinatorial therapy results. One such
example is osteonecrosis, an effect known to be caused when radium-223 dichloride therapy is combined
with (current or prior) bisphosphonate treatment (osteonecrosis of the jaw) or in patients under a
long-term treatment with glucocorticoids [4,20]. Also, chemotherapy may affect myelosuppression
incidence [21], making it one of the major concerns regarding radium-223 dichloride administration
and its principal side effect [4,5].
Indeed, our analysis confirms the manifestation of known radium-223 dichloride side effects such
as hematotoxicity; specifically, anemia, thrombocytopenia, neutropenia and bone marrow toxicity
were some of the most frequently reported reactions in radium-223 dichloride’s AEs. In line with
its toxicological profile, gastrointestinal disorders (such as diarrhea, vomiting, and nausea) during
radium-223 dichloride treatment were also confirmed. These events can be of particular significance
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with respect to patient management since they may lead to dehydration, thus requiring careful
monitoring of patient oral intake and fluid status [5].
Such implications also highlight the importance of computationally analyzing real world and
big data towards their translation into more informed patient management [22–25]. For example, the
high bone and/or back pain signals observed in radium-223 dichloride AEs may likely be attributed to
progression of skeletal disease burden. However, physicians should consider also the possibility that
patient symptomatology is, among others, due to a seldom described clinical flare phenomenon caused
by the treatment, or other events such as spinal cord compression or fractures [26].
Characteristically, regulatory authorities have recently posed concerns regarding the incidence of
fractures when radium-223 dichloride is combined with abiraterone and prednisone/prednisolone [14].
In our dataset, occurrence of fractures was the same for both cohorts A and B. Specifically, the
High Level Group Term (HLGT) of MedDRA (level 2 category) fractures linked to 2.7% of both sets’
cases—namely, to 28 and 15 AEs of cohorts A and B, respectively. Interestingly, radium-223 dichloride
was co-medicated with anti-androgens in five out of the fifteen AEs of Cohort B that reported fractures.
Nevertheless, we expect that deriving conclusive hypotheses on the existence of potential synergistic
effects between these agents would require examining more data gathered from additional studies in
this context.
Previous studies report that abiraterone’s mechanism of action involves suppression of androgen
production by blocking the enzyme activity of Cytochrome P450 17 α-hydroxylase (CYP17), providing
an inhibitory effect on CRPC progression [27]. However, both radiation therapy and androgen
receptor-directed therapy can induce significant oxidative stress through an increase of reactive oxygen
species, potentially causing various side effects. Moreover, androgen receptor-directed therapies
can induce hormonal imbalance with induction of glucocorticoid receptor expression in resistant
CRPC clones [28,29]. Thus, the combination treatment of radium-223 dichloride, abiraterone and
prednisone/prednisolone could potentially exacerbate the toxicity issue raised by the recently published
preliminary data of the phase III trial in metastatic CRPC [12–14]. However, from FAERS data only
it cannot be derived which are the potential mechanisms underlying the effects of combinatorial
therapy on the toxicological profile of radium-223 dichloride, emphasizing thus in addition the
importance of being able to molecularly analyze real world AE data coming from spontaneous
reporting systems [17,30,31].
Moreover, AE data may also come with other limitations [17,22,23]. For example, the severity
of conditions (indications, reactions) reported in FAERS is not graded and their occurrence cannot
be confirmed. In addition, the public FAERS dataset may include reporting errors; it also does
not adequately suffice to clearly determine whether some of the observed reactions reflect disease
symptoms and patient conditions or not. The high occurrence of reactions representing a general
health deterioration status (such as malaise, fatigue and asthenia) in radium-223 dichloride AEs may
thus indicate side effects caused by the treatment but may also reflect signs of disease grade and/or
tumor progression. Furthermore, FAERS contains only AEs and is therefore biased without proper
normalization considering reference/control data. In turn, reaction occurrence in our dataset may differ
from radium-223 dichloride’s product characteristics summary [4,5]. Last, public FAERS does not
come with (potentially important) information regarding a patient’s history (e.g., therapies, allergies,
co-morbidities) prior to their AE.
Furthermore, one other important parameter regarding the use of radiopharmaceuticals is
dosimetry. At present, radium-223 dichloride is applied according to standard fixed administrations
at 4-week intervals, modified according to patient weight. However, therapy individualization and
optimization would also involve internal dosimetry calculations. Although the nature of α-irradiation
in a clinical context is not clearly understood [32], different pharmacokinetic, biodistribution and
dosimetry studies have demonstrated a rapid clearance of radium-223 from the blood with the gut
being the main route of excretion [33,34], partially explaining the high incidence of gastrointestinal
track side-effects. Regarding bone marrow toxicity, it is not expected that uptake of radium-223 on bone
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surfaces will irradiate the marrow cavities uniformly, due to the high linear energy transfer and short
path length of α-particles [32]. Interestingly, a spatial gradient of hematopoietic stem and progenitor
cells has been demonstrated within human cancellous bone with higher concentrations near the bone
surfaces. The dosimetric implication of this finding is significant in terms of radium-223 dichloride
treatment, in which the absorbed dose is non-uniformly delivered across the bone marrow, leading to
higher absorbed doses in these radiosensitive cells of interest [35]. On the other hand, patient dosimetry
data in tumor lesions, which could potentially lead to an increase of the radiopharmaceutical dose
administered without increasing the incidence of side effects, are limited. Moreover, despite being
feasible, the clinical benefit of tumor macrodosimetry of radium-223 remains to be investigated [36].
Finally, our AE analysis could benefit further from the examination of additional data regarding
laboratory and clinical parameters (e.g., baseline hemoglobin values, number of radium-223 dichloride
injections and dosimetry, treatment duration, cycles, and dosage). However, such data are not readily
available or straightforward to extract from the public FAERS dataset. Nonetheless, FAERS reports
contain a large breadth of drug-induced phenotypic effects observed in AEs that can be further analyzed
by capitalizing upon its integration with additional levels of information [17,31]. Also, AEs comprise an
augmented data stream capturing real-world scenarios regarding therapeutic uses and combinations,
phenotypes and conditions not studied in clinical-trials, as well as include information for many more
patients [17,30]. Therefore, with our work, we also highlight the importance of standardizing and
structuring real world data and invite the development of more systematic approaches that strive to
efficiently combine outcome data with molecular etiologies and clinically significant information. Last,
we envisage that our findings will provide additional context to the current efforts to characterize
evidence regarding the safety of radium-223 dichloride.
5. Conclusions
Radium-223 dichloride (Xofigo®) is a radiopharmaceutical approved for the treatment of CRPC
patients with symptomatic bone metastases and no known visceral metastatic disease. Despite
its favorable safety profile, recent evidence suggests that its combined use with abiraterone and
prednisone/prednisolone may be associated with increased fracture and mortality risk. While our
results acknowledge these concerns posed by the regulatory authorities (EMA, FDA), we find that
deriving definitive hypotheses on this aspect from our AE data would require examining a larger
sample of patients and we call for more studies to help gather additional data regarding the combined
application of these agents. Overall, our results recapitulate known side effects observed with
radium-223 dichloride and confirm hematotoxicity and gastrointestinal disorders as the main patient
safety concerns. While public FAERS-based analytics might benefit from the consideration of additional
clinical information, our study emphasizes the importance of computationally analyzing patient
outcome information so as to support the gain of clinical insight directly from real world data.
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